The Filing Desk

Ovid Therapeutics

OVID · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

OVID · Last close · November 13, 2026
$2.54
Value Ovid Therapeutics yourself

Ovid Therapeutics' revenue rose 1181.3% to $7 million in fiscal 2025. Its operating margin was −585.2%, up from −10,933.8% a year earlier. Free cash flow was −$38 million.

Ovid Therapeutics Inc. Latest fiscal year ended December 31, 2025 10-K filed March 18, 2026 · 0001628280-26-019438 Updated
Revenue
$7M
1181.3%
Operating margin
−585.2%
10348.5 pts
Net income
−$17M
 
Free cash flow
−$38M
 
Return on equity
−17.5%
16.4 pts
Market cap
$180M
Nov 13 close
P/E
—
 

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Ovid Therapeutics does

Ovid Therapeutics is a drug developer with no products on the market. It works on small-molecule medicines for brain disorders in which nerve cells become overactive, such as epilepsy and psychosis. It has in-licensed and developed drug candidates that it hopes will work in new ways.

Its programs are in clinical trials for seizures that resist treatment, rare childhood epilepsies such as tuberous sclerosis complex seizures and infantile spasms, psychosis linked to Parkinson's disease and Lewy body dementia, and schizophrenia. It also has early programs for other forms of psychosis and mood disorders.

Because it has nothing to sell yet, Ovid describes its plan as moving these drug candidates through clinical trials and winning approval. It says it may also earn money from milestone payments and from partnerships with other companies. It competes with other drug developers for the same patients and approvals. It says it intends eventually to sell its own medicines.

Its biggest risks, as it describes them

  • It needs more capital to fund its work, and expects to keep losing money.
  • Its drug candidates may fail in trials or be denied approval; early results may not predict later ones.
  • Patient enrollment in trials can be slow and costly, and trials can be delayed or stopped.
  • Its drug candidates may cause side effects that delay or prevent approval.
  • Competition from other companies developing medicines for epilepsy and psychosis.
From Ovid Therapeutics's annual report on Form 10-K, filed March 18, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Ovid Therapeutics lost money in fiscal 2025: a net loss of $17 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1881291065390
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio12.9x18.8x9.6x5.3x9.0x
Quick ratio12.9x18.8x9.6x5.3x9.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Ovid Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Ovid Therapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−11,763.0%−9,854.4%652.7%
Altman Z''−2.95−9.050.80
Accruals ratio−4.4%25.0%17.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassFailFail
Debt fell relative to assets———
Current ratio roseFailFailPass
Share count didn't riseFail——
Gross margin rose———
Revenue rose relative to assetsFailPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Ovid Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Ovid TherapeuticsFY251,181.3%−585.2%−528.6%———
Xenon PharmaceuticalsFY25—−4,974.3%−3,732.2%———Compare
ImmunomeFY25−23.2%−3,228.8%−2,890.1%———Compare
Aclaris TherapeuticsFY25−58.2%−975.9%−603.4%———Compare
PrecigenFY25146.7%−1,141.1%−927.6%——2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue————132082017
Revenue growth—————1,551.6%−99.3%−73.9%44.4%1,181.3%
Gross profit——————————
Research and development10503442634725293726
Operating income−22−65−53−61−81124−56−59−62−42
Net income−22−65−52−60−81123−54−52−26−17
Diluted EPS (US$)−2.28−3.35−2.11—−1.391.76−0.77−0.74——
Diluted shares (millions)101925—58687071——
Cash flow
Cash from operations−18−32−46−51−52119−55−46−56−38
Capital expenditure0000001000
Free cash flow−18−32−46−51−52118−56−46−56−38
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation4675857765
Balance sheet at fiscal year end
Cash and short-term investments52874277—1881291065390
Debt incl. finance leases——————————
Total assets539048817619415514492151
Total liabilities46911321523562420
Shareholders' equity49833970441801328868131
Margins and ratios
Gross margin——————————
Operating margin————−645.4%59.6%−3,696.4%−15,122.7%−10,933.8%−585.2%
Net margin————−642.3%59.0%−3,604.7%−13,351.8%−4,670.1%−240.1%
Free cash flow margin————−409.9%56.8%−3,756.6%−11,689.0%−9,898.8%−528.6%
Rule of 40 (growth + FCF margin)—————1,608.4%−3,855.8%−11,763.0%−9,854.4%652.7%
Return on capital——————————
Return on equity—−97.7%−85.0%−111.1%−142.6%110.0%−34.7%−47.6%−33.9%−17.5%
Return on assets—−91.0%−75.8%−94.1%−103.4%90.8%−31.0%−35.0%−22.4%−14.3%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Ovid Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Ovid Therapeutics.